Pricing surge masks weak volume; margin gains at risk if war-driven tailwinds fade

Delivered ₹703.6 Cr, +19.0% YoY; corroborated

Q1 FY27 utilization was 65%, not 75%; below prior guidance

Only 3.5% aggregate volume growth; majority was price-driven, not demand-driven

Delivered 13.7% OPM; margin expansion supported by elevated API pricing from West Asia conflict

Delivered ₹50.1 Cr PAT; prior year included ₹15 Cr tax refund; math checks out but highlights tax dependency

Prior guidance 75% early FY27; actual Q1 65%. Still progressing but slower than expected. Sept/Dec target 80–90%.

Q1 achieved 3.5% volume growth, price-driven; prior FY26 calls guided 12–15% volume growth for FY27. Early miss signals execution headwinds.

13.8% EBITDA margin hit, but management now emphasizing it is temporary and contingent on war-driven pricing. 14–15% target conditional on utilization + pricing stabilization.

Pricing +15–20% YoY due to war; major spike in March–April, now moderating. Scaling capacity 1,400 to 2,200 tons/month; USFDA approval in 10–12 months opens US and EU markets. Currently EDQM approved, targeting 500–550 tons USFDA capacity.

Volatile; not calling sustained recovery yet. Stable pricing and margins possible even if prices moderate. Phase 1 greenfield asset turn ~1.5x; Phase 2 brownfield ~3–4x due to shared infrastructure. Sayakha 50% captive for antidiabetic, margins over revenue.

Methylamine at 65% (~60 tons/day, 3,500 tons Q1); Spec Chem ₹82 Cr revenue Q1 expected to repeat/improve. Metformin expansion at Sarigam (not Sayakha): 1,400 → 1,700 tons plus USFDA block. E-22 USFDA plant (4–5 active products, EU only, US samples in approval).

Q1: 3.5% volume, 16–17% pricing aggregate growth. Price spike depressed demand; expecting volume recovery as prices stabilize. H2 pricing should ease; demand should rebound once downstream inventory normalizes. Export less impacted; domestic demand pressure on antibiotics/antidiarrheals.

14% already crossed in Q1 (with write-offs). 15% 'very easy' once greenfield utilization improves + salicylic acid plant stabilizes. For volume: 10–15% achievable next 2 years on 70% current capacity utilization. Phase 2 capex will drive higher returns.

USFDA API approval after 10-year wait now opens US + EU. 9 European-CEP approvals filed. E-22 plant producing 4–5 products (EU only, US in BD). Formulations 70%+ exports. Regulated markets still in BD phase; margins to expand as volume scales.

Q1 60–70% external procurement; already declining. By Sept/Dec expect 80–90% captive. Adds ~1% gross contribution at peak. Coupled with better utilization, could drive 200 bps EBITDA improvement if pricing stabilizes.

Q1 achieved only 3.5% volume growth; price-driven. Management now says 10–15% achievable over next 2 years, implying slower near-term ramp than originally guided.

Q1 delivered 13.8%, but management says 'almost there at 14%' and 15% 'very easy' once utilization and pricing normalize. Conditional on greenfield ramp + salicylic acid stabilization.

₹600 Cr deployed over last 2 years. Ongoing Phase 2 brownfield capex at Sayakha, Tarapur, and Baddi mentioned; no revised annual guidance provided.

Q1 EBITDA margin and PAT heavily lifted by war-driven API pricing (+15–20% metformin, +16–17% aggregate). Management flags not sustainable; margin compression likely if geopolitical situation stabilizes.

Sayakha facility at 65% vs. 75% prior guidance for early FY27; methylamine product hit 65% utilization but other products lower. Ramp trajectory below expectations.

Q1 volume growth only 3.5%, entirely price-driven; FY27 target was 12–15%. High-price environment dampens formulation purchaser demand, particularly antibiotics/antidiarrheals.

Tarapur salicylic acid facility struggling; only 67 tons produced in Q1. Chinese dumping of pricing drove shift to derivatives strategy. Anti-dumping duty delayed 1+ year.

USFDA E-22 facility (4–5 active products) only supplying EU so far; US market still in sample/vendor-approval phase. Current revenue doesn't reflect profitability of regulated markets.